Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.61 USD
+0.02 (0.77%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.61 USD
+0.02 (0.77%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Why Is Allogene Therapeutics (ALLO) Up 7.4% Since Last Earnings Report?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs
by Zacks Equity Research
With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.
Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation
by Zacks Equity Research
The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.
Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies
by Zacks Equity Research
Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month.
Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.
Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA
by Zacks Equity Research
The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.
Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold
by Zacks Equity Research
Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.
Company News for Oct 11, 2021
by Zacks Equity Research
Companies in The News Are: ACCD,CCXI,ALLO,WMT
Are Options Traders Betting on a Big Move in Allogene (ALLO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.
Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies
by Zacks Equity Research
The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.
Gilead (GILD) Files sBLA to FDA for Yescarta Label Expansion
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary, Kite, submits an sBLA to the FDA for Yescarta to treat relapsed/refractory large B-cell lymphoma in the second-line setting.
Allogene Therapeutics (ALLO) Up 9.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene's (ALLO) CAR T Therapy Gets Orphan Drug Status
by Zacks Equity Research
Allogene's (ALLO) CAR T therapy, ALLO-715, gets orphan-drug designation in the United States. It is a potential treatment for multiple myeloma and other BCMA-positive malignancies.
Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.
Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag
by Zacks Equity Research
Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.
Gilead's (GILD) Kite Announces Positive Data on Yescarta
by Zacks Equity Research
Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.
Why Is Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.
Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.
ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.
Allogene Therapeutics (ALLO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 47.92% and 56.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag
by Zacks Equity Research
FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.
Allogene Therapeutics (ALLO) Up 3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL
by Zacks Equity Research
Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.